ACE2 and COVID-19: According to network pharmacology and molecular docking studies, quercetin has exhibited the ability to bind to the active sites of both 3CLpro via interactions with various amino acids and ACE2, thus possibly posing as a potential therapy for COVID-19-induced AKI [191].